Effects of the NA+ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation

J Cardiovasc Electrophysiol. 2004 Dec;15(12):1396-401. doi: 10.1046/j.1540-8167.2004.04430.x.

Abstract

Introduction: Na+ channel blockers are used to treat atrial fibrillation (AF). However, the effects of Na+ channel blockers on the electrophysiologic properties of pulmonary veins (PVs) are not well characterized. The aim of the present study was to evaluate the effect of the pure Na+ channel blocker pilsicainide on the PVs.

Methods and results: PV mapping using a basket catheter was performed in 28 patients with paroxysmal AF. Twenty-eight PVs, including 20 left superior and 8 right superior PVs, were studied. Programmed stimulation was performed in the distal PV and PV-left atrial (LA) junction before and after infusion of pilsicainide (1 mg/kg). Pilsicainide significantly prolonged the effective refractory period (ERP) of the distal PV from 163 +/- 44 msec to 192 +/- 53 msec (P < 0.001), PV-LA junction from 227 +/- 48 msec to 235 +/- 52 msec (P < 0.05), and LA appendage from 225 +/- 55 msec to 245 +/- 48 msec (P < 0.05). Pilsicainide significantly prolonged the conduction time from the distal PV to PV-LA junction from 45 +/- 14 msec to 70 +/- 26 msec (P < 0.0001). In 3 of 5 patients who experienced AF termination with pilsicainide, PV-LA conduction block was observed just before AF termination.

Conclusions: Pilsicainide can modify ERP heterogeneity and conduction properties in the PV and at the PV-LA junction. Because the PV and PV-LA junction have important roles as substrates for AF maintenance, pilsicainide may terminate AF by pharmacologic PV isolation.

MeSH terms

  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / physiopathology*
  • Electrophysiologic Techniques, Cardiac*
  • Female
  • Humans
  • Infusions, Intravenous
  • Lidocaine / analogs & derivatives*
  • Lidocaine / pharmacology*
  • Male
  • Middle Aged
  • Pulmonary Veins / drug effects*
  • Pulmonary Veins / physiopathology*
  • Sodium Channel Blockers / pharmacology*
  • Treatment Outcome

Substances

  • Sodium Channel Blockers
  • Lidocaine
  • pilsicainide